Matthew Wall

Neuroscientist

Data updated

Papers

17 publications

Trials

0 clinical trials

Research Footprint

Matthew Wall appears in 17 tracked papers (2013–2026), most studied alongside Psilocybin, MDMA and LSD, across Neuroimaging & Brain Measures, Depressive Disorders and Healthy Volunteers.

Most-cited paper: Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms (585 citations).

Frequent co-authors: David Nutt, Robin Carhart-Harris and Leor Roseman.

Background & Research

Matthew Wall is a neuroimaging scientist based at Imperial College London who specialises in functional MRI studies of psychoactive compounds and their effects on human brain function. He has collaborated with leading psychedelic research groups and clinical teams to image acute and short-term brain changes after administration of psilocybin, LSD and MDMA, and has acted as principal imaging scientist on early fMRI investigations of psilocybin in treatment-resistant depression. His methodological work spans task-evoked and resting-state paradigms and includes studies linking musical and emotional processing to drug-induced changes in brain activity.

Wall's contributions include empirical studies of LSD- and MDMA-related modulation of striato‑cortical connectivity, investigations of music‑evoked brain responses under LSD, analyses of first‑use psilocybin brain changes, and naturalistic work on MDMA/ecstasy and social behaviour. He is a co-author of recent reviews charting the role of neuroimaging in psychedelic drug development and has helped to integrate network‑level and affective neuroscience perspectives into translational research on psychedelic-assisted therapies.

Affiliations

Institutions, companies, and organisations Matthew Wall is associated with.